降钙素基因相关肽家族的受体活性修饰蛋白

降钙素基因相关肽家族中的降钙素、胰淀粉样酶、两种降钙素基因相关肽和肾上腺髓质素具有相似的结构。受体活性的修饰蛋白（RAMP）是新近从蟾蜍卵细胞中发现并克隆出来的蛋白质。受体活性修饰蛋白是具有单一跨膜功能域的蛋白,可调节降钙素的受体样受体（CRLR）向细胞膜的转运和识别配体的特异性。不同的RAMP可与降钙素受体试样受体或降钙素受体结合表现为对不同配体具有亲和的、不同的受体表型而决定了体内的生物学效应。RAMP1转运的末端糖基化的成熟的CRLR蛋白,使CRLR表现为功能性的降钙素基因相关肽（CGRP）受体表型;RAMP2转运的CRLP是核心糖基化的未成熟的CRLR蛋白,使CRLR表现为功能性的肾上腺髓质素（Adm）受体表型。RAMP亦可与降钙素受体作用产生Amylin受体表型。     

降钙素基因相关肽受体组分蛋白

降钙素基因相关肽受体组分蛋白(calcitonin gene-related peptide-receptor component protein,CGRP-RCP)是降钙素基因相关肽受体的一个具有146/148个氨基酸的胞内膜周边蛋白,特异地与降钙素受体样受体(calcitonin receptor-like receptor,CRLR)相互作用并促进CGRP和肾上腺髓质素的信号跨膜转导,现认为CGRP-RCP也是G蛋白偶联受体中一个动态的调节器。CGRP-RCP的mRNA在人和鼠的几乎所有组织均可检测到,在小鼠睾丸中分布尤其明显。在哺乳动物中,CGRP-RCP与C17(酵母菌中聚合酶III的必需亚基)是直系同源蛋白,人体的CGRP-RCP能取代酵母中的C17,发挥与C17相同的生物学作用。     

受体活性修饰蛋白研究进展

受体活性修饰蛋白(receptor activity-modifying proteins,RAMPs)属于单跨膜蛋白家族,分三个结构域,RAMP的N端和跨膜区决定本身的功能和受体表型,胞内C端对于配体的信号传导和受体循环有重要作用。目前发现有三个成员:RAMP1、RAMP2和RAMP3。RAMPs通过改变G蛋白偶联受体的糖基化,作用于配体结合区域来调节受体表型。RAMP1与降钙素受体样受体(calcitonin receptor like receptor,CRLR)结合表现出降钙素基因相关肽(calcitonin gene-related peptide,CGRP)受体表型:RAMP2和RAMP3与CRLR结合则对肾上腺髓质素(adrenomedullin,AM)表现高亲和力,与降钙素受体(calcitonin receptor,CTR)结合则作为胰淀粉样酶(amylin,AMY)受体。由此可见,RAMPs不仅调节受体与配体结合,还影响细胞内的蛋白相互作用调节细胞内信号传导来影响细胞的增殖、迁移、分化等生物学特性。RAMPs还对心血管系统的病理生理有重要调节作用。     

肾上腺髓质素和降钙素基因相关肽受体在血管平滑肌细胞的脱敏—受体活性修饰蛋白的作用

新近研究发现,肾上腺髓质素（adrenomedullin,ADM)和降钙素基因相关肽（calcitonin gene-related peptide,CGRP)均能与降钙素受体样受体（calcitoni receptor-like receptor,CRLR)结合,其配体特异性由受体活性修饰蛋白（receptor activity-modifying protein RAMP)调控,本工作在离体培养的大鼠胸主动脉血管平滑肌细胞（vsacular smooth muscle cells,VSMCs)上观察ADM和CGRP受体脱敏现象,以探讨CRLR／RAMP假说在心血管组织方面的意义,用无血清培养基（serum-free medium,SFM)和含有10^-8mol/L ADM,CGRP和肾上腺髓素质前体原N－末端20肽（proadrenomedullin N-terminal 20 peptide PAMP）的SFM培养,再用10^-8mol/L ADM或 CGRP和磷酸二酯酶的抑制剂异丙基次黄苷（isobutyryl methyxanthine,IBMX)与VSMCs进行第二次孵育,然后收集细胞,测定VSMCs cAMP含量。10^-8mol/LADM,CGRP和PAMP单独与VSMCs孵育,VSMCs cAMP含量分别较SFM组高191％（P＜0．01）,385％（P＜0．01）和67％（P＜0．05）,预先用10^-8mol/L ADM ak CGRP与VSMCs孵育可降低随后的CGRP刺激VSMCs产生cAMP,分别较单次CGRP育少44％（P＜0．05）和48％（P＜0．01）,预先用100nmol/L蛋白激酶A（PKA）抑制剂H－89处理VSMCs,可完全阻断ADM和CGRP预处理诱导的第二次CGRP刺激的VSMCs cAMP含量减少,表明VSMCs对CGRP的脱敏过程是通过PKA途径实现的,预先用ADM,CGRP处理VSMCs后,用ADM第二次孵育,细胞内cAMP含量与单次ADM孵育无明显改变,PKA抑制H－89与VSMCs孵育,无论对欠ADM刺激或对ADM和CGRP处理的第二次刺激的cAMP生成均无影响,用PAMP处理VSMCs后,ADM和CGRP的第二次刺激的VSMCs cAMP水平无明显改变（P＞0．05）。结果提示,在离体培养的大鼠VSMCs,ADM epc wsg i euk txgtdmj CGRP受体对预先用ADM和CGRP处理后的激动剂的第二次刺激都脱敏,表明ADM和CGRP的脱敏现象不一致。     

受体活性修饰蛋白新功能

受体活性修饰蛋白 (receptoractivitymodifyingproteins ,RAMP)可调节II型G 蛋白偶联受体如降钙素受体样受体 (calcitoninreceptor likereceptor ,CRLR)和降钙素受体 (calcitoninreceptor,CTR)与降钙素基因相关肽家系 [calcitoningene -relatedpeptide 1,2 (CGRP1,2 ) ,amylin ,adrenomedullinandcalcitonin]成员结合 ,并调节CRLR与配体结合的特异性和受体表型 ,介导CGRP家系各成员的生物学效应。RAMPs的上述作用已得到学术界的认可。最近ArthurChristopulos等发现RAMPs除了与CGRP家系受体结合外 ,还可与其它的II型G 蛋白…     

降钙素和降钙素基因相关肽的选择性表达

降钙素和降钙素基因相关肽(CT/CGRP)由同一基因编码,该基因结构及其5＇端侧翼序列决定了它能够在甲状腺C细胞以及中枢和外周神经细胞生成不同的表达产物.这种选择表达调控决定多细胞生物的发育、性别分化和进化.如果表达失控将导致甲状腺髓样瘤(MTC)和骨质疏松症等疾病.文章对该基因的结构和选择性表达调控进行了综述.     

降钙素基因相关肽的研究进展

降钙素基因相关肽（ＣＧＲＰ）是由３７个氨基酸残基构成的生物活性多肽,与降钙素（ＣＴ）源子一个共同的基因。ＣＧＲＰ分布广泛,具有很强的血管扩张、降低血压以及心肌正性肌力作用等,并参与心血管系统稳态的调节。目前,ＣＧＲＰ已能人工合成,将为某些心血管疾病如高血压、心肌缺血、痉挛性或闭塞性周围血管疾病等的治疗提供一条崭新的途径。     

降钙素基因相关肽（CGRP）受体的纯化和鉴定

降钙素基因相关肽（ＣＧＲＰ）为３７肽,它在体内主要分布于神经系统和心血管系统,是较强的扩张血管物质。人们已认识到脑部的ＣＧＲＰ最多,由于新鲜猪脑来源丰富,故我们选用猪脑为材料来纯化ＣＧＲＰ受体。以期为该受体的深入研究提供足够的材料和奠定基础,纯化的受体将用于制备抗ＣＧＲＰ受体的单克隆抗体,为了从猪脑中纯化ＣＲＲＰ受体,首先用含有胆盐的磷酸盐缓冲液将该受体从猪脑细胞膜上解离下来,解离下来的受体量较多,而杂蛋白较少,且受体活性可保持较长时间不降低。以离子交换柱层析（ＱＡＥ－Ｓｅｐｈａｄｅｘ－Ａ－２５）进行初步分离纯化,再用化学合成的ＣＧＲＰ与活化的琼脂糖（Ａｆｆｉ－Ｇｅｌ－１０,Ｂｉｏ－Ｒａｄ公司产品）制备的亲和层析柱进行亲和层析,取得的纯化受体保留了与１２５Ｉ－ＣａＧＲＰ结合的能力,而与降钙素（Ｃａｌｃｉｔｏｎｉｎ）神经肽Ｙ（ＮｅｕｒｏｐｅｐｔｉｄｅＹ）和Ｋａｔａｃａｌｃｉｎ等无交叉反应,但与有４６％氨基酸序列同源性的Ａｍｙｌｉｎ有一定交叉反应。纯化的受体经ＳＤＳ－聚丙烯酰胺凝胶电泳和高压液相色谱（ＨＰＬＣ）鉴定呈现单一蛋白条带或蛋白峰,其位置对应分子量为６６ｋＤ。     

降钙素基因相关肽（CGRP）受体的纯化和鉴定

降钙素基因相关肽（ＣＧＲＰ）为３７肽,它在体内主要分布于神经系统和心血管系统,是较强的扩张血管物质,人们已认识到脑部的ＣＧＲＰ最多,由于鹇猪脑来源丰富,故我们选用猪脑为材料来纯化ＣＧＲＰ受体。以期为该受体的深入研究提供足够的材料和奠定基础,纯化的受体将用于制备抗ＣＧＲＰ受体的单克隆抗体。为了从猪脑中纯化ＣＲＲＰ受体,首先用含有胆盐的磷酸盐缓冲液将该受体从猪脑细胞膜上解离下来,解离下来的受体量较多,     

Activation of Calcitonin Receptor and Calcitonin Receptor-like Receptor by Membrane-anchored Ligands

G protein-coupled receptors (GPCRs) are the most important pharmaceutical targets, and more than 40% of drugs in use today modulate GPCR signaling. A major hurdle in the development of therapies targeting GPCRs is the drug candidate''s nonselective actions in multiple tissues. The ability to spatially control GPCR signaling would provide a venue for developing therapies that require targeted GPCR signaling. Here, we show that the fusion of a RAMP1 co-receptor with the calcitonin gene-related peptide (CGRP), or calcitonin, transforms the RAMP1 from a co-receptor to bona fide membrane-anchored ligands (CGRP-RAMP1 and CAL-RAMP1). The CAL-RAMP1 selectively activates the calcitonin receptor (CR), whereas, the CGRP-RAMP1 activates both the calcitonin receptor-like receptor (CLR) and CR. Unlike a free peptide, which moves freely in the extracellular space and differentiates targets based on molecular affinity, the anchored CGRP-RAMP1 and CAL-RAMP1 ligands confine their activities to individual cells. In addition, our study showed that a CGRP8–37-RAMP1 chimera, but not RAMP1, functions as an antagonist for CGRP-RAMP1-mediated signaling, suggesting that the activation of CLR by CGRP-RAMP1 shares similar molecular mechanisms with the CGRP-mediated activation of CLR/RAMP1 receptor complexes. Taken together, our finding thus provides a novel class of ligands that activate CR and CLR exclusively in an autocrine manner and a proof-of-concept demonstration for future development of targeted therapies aimed at these receptors in specific cell populations.     

Functional Coupling of G Proteins to Endothelin Receptors Is Ligand and Receptor Subtype Specific

1. The aims of the present study were (a) to determine the identity of the G proteins with which the endothelin receptor interacts and whether this interaction is subtype specific and (b) to determine whether agonist exposure can result in specific coupling between the endothelin receptor and G proteins.2. Coupling between endothelin A (ET_A) or endothelin B (ET_B) receptors and G proteins was assessed in two fibroblast cell lines, each expressing one receptor subtype. Four ligands, ET-1, ET-3, SRTXb, and SRTXc, were used for receptor stimulation. The G protein -subunit coupled to the receptor was identified by immunoprecipitation with an antibody against the endothelin receptor and immunoblotting with specific antibodies against different G protein -subunits.3. Unstimulated ET_A and ET_B receptors (ET_AR and ET_BR, respectively) were barely coupled to G_o. The unstimulated ET_AR coimmunoprecipitated with G_i3, whereas the unstimulated ET_BR was much less strongly coupled to G_i3. The coupling of ET_BR to G_i1G_i2 -subunits was much stronger than the coupling of ET_AR to these -subunits. Stimulation with the different ET agonists also resulted in differential coupling of G proteins to the receptor subtypes. All four ligands caused a strong increase in coupling of the ET_BR to G_i3, whereas coupling of the ET_AR to this subunit was not affected by ET-1 and was even decreased by SRTXc. On the other hand, all four ligands caused a much greater increase in the coupling of ET_AR to G_q/G₁₁ than in the coupling of ET_BR to these -subunits. Ligand-induced coupling between the receptors and the G_i1 and G_i2 -subunits is similar for the two receptor subtypes. The same was true for ligand-induced coupling of the receptors to G_o, except that ET-3 increased the coupling of this -subunit to ET_BR and decreased the coupling to ET_AR. Taken together, the results of this study show that coupling between ET receptors and G proteins is ligand and receptor subtype specific.4. It remains to be established whether this diversity of receptor–G protein coupling is of relevance for the various endothelin signaling pathways and/or pathological states.     

Expression of the calcitonin receptor, calcitonin receptor-like receptor, and receptor activity modifying proteins during osteoclast differentiation

The expressions of the calcitonin receptor (CTR), the calcitonin receptor-like receptor (CLR), the receptor activity-modifying proteins (RAMP) 1-3, and of the receptor component protein (RCP) have been studied in mouse bone marrow macrophages (BMM) during osteoclast differentiation, induced by treatment with M-CSF and RANKL. Analyses of mRNA showed that CLR and RAMP1-3, but not CTR, were expressed in M-CSF stimulated BMM. RANKL gradually increased CTR mRNA, transiently enhanced CLR and transiently decreased RAMP1 mRNA, but did not affect RAMP2, RAMP3, or RCP mRNA. However, RANKL did not affect protein levels of CLR or RAMP1-3 as assessed by Western blots or FACS analyses, whereas immunocytochemistry showed enhanced CTR protein. Analyses of cAMP production showed that BMM cells expressed functional receptors for calcitonin gene-related peptide (CGRP), amylin, adrenomedullin, and intermedin, but not for calcitonin and calcitonin receptor stimulating peptide (CRSP), but that RANKL induced the expression of receptors for calcitonin and CRSP as well. Calcitonin, CGRP, amylin, adrenomedullin, intermedin, and CRSP all down regulated the CTR mRNA, but none of the peptides caused any effects on the expression of CLR or any of the RAMPs. Our data show that BMM cells express receptors for CGRP, amylin, adrenomedullin, and intermedin and that RANKL induces the formation of receptors for calcitonin and CRSP in these cells. We also show, for the first time, that the CTR is not only down regulated by signaling through the CTR but also by the peptides signaling through CLR/RAMPs.     

Identification, structural determination, and biological activity of bovine and canine calcitonin receptor-stimulating peptides

We have recently identified in porcine brain a series of new peptides, designated calcitonin receptor-stimulating peptide-1 (CRSP-1), CRSP-2, and CRSP-3, but failed to find their counterparts in humans and rodents by either database searching or experimental cross-hybridization. In this study, we isolated cDNAs encoding precursors of bovine CRSP-1, canine CRSP-1, and canine CRSP-2 from their thyroid cDNA libraries. Although the deduced mature amino acid sequences of bovine and canine CRSP-1s and canine CRSP-2 showed identity with their respective porcine CRSP counterparts, none of them had a C-terminal amide structure. In LLC-PK(1) cells endogenously expressing the calcitonin (CT) receptor, bovine and canine CRSP-1s enhanced the cAMP production, while canine CRSP-2 did not stimulate it at all. Equine CGRP-I had a high identity in its amino acid sequence with porcine CRSP-1 and stimulated LLC-PK(1) cells at a potency comparable to that of porcine CT. None of these CRSPs or equine CGRP-I stimulated the CT-like receptor, even in the presence of receptor activity-modifying proteins. These results demonstrate that CRSP-1, a new class of biologically active peptide, is present in animals evolutionarily close to pigs and induces its activity through the calcitonin receptor, suggesting a wide existence and common properties of this peptide in mammals.     

Receptor activity modifying proteins interaction with human and porcine calcitonin receptor-like receptor (CRLR) in HEK-293 cells

Calcitonin gene-related peptide (CGRP) and adrenomedullin (ADM), two closely related peptides, initiate their biological responses through their interaction with calcitonin receptor-like receptor (CRLR). The CRLR receptor phenotype can be determined by coexpression of CRLR with one of the three-receptor activity modifying proteins (RAMPs). In this report, we characterized the pharmacological properties of the human or porcine CRLR with individual RAMPs transiently expressed in human embroynic kidney cell line (HEK-293). Characterization of RAMP1/human or porcine CRLR combination by radioligand binding ([¹²⁵I] hCGRP) and functional assay (activation of adenylyl cyclase) revealed the properties of CGRP receptor. Similarly characterization of RAMP2/human or porcine CRLR and RAMP3/human or porcine CRLR combination by radioligand binding ([¹²⁵I]rADM) and functional assay (activation of adenylyl cyclase) revealed the properties of ADM (22–52) sensitive-ADM receptor. In addition, porcine CRLR/RAMP2 or 3 combination displayed specific high affinity [¹²⁵I] hCGRP binding also. Also, co-transfection of porcine CRLR with RAMPs provided higher expression level of the receptor than the human counterpart. Thus the present study along with earlier studies strongly support the role of RAMPs in the functional expression of specific CRLRs.     

类甜蛋白的结构特征以及功能研究进展

类甜蛋白是一种具有多种生物学活性及重要功能的植物防御蛋白,属于病程相关蛋白。近年来关于类甜蛋白具有抗真菌活性的研究较多。类甜蛋白具有葡聚糖酶活性,能结合并降解真菌细胞壁的组成成分—β-1,3葡聚糖酶。在三维晶体结构中类甜蛋白表面的一个酸性“V”字形裂缝对其抗真菌活性起着至关重要的作用。对类甜蛋白结构与功能的关系,不同植物中类甜蛋白的生物学特性,以及国内外基因工程中类甜蛋白基因的应用研究进展进行了综述。     

Functions of the extracellular histidine residues of receptor activity-modifying proteins vary within adrenomedullin receptors

Receptor activity-modifying protein (RAMP)-2 and -3 chaperone calcitonin receptor-like receptor (CRLR) to the plasma membrane, where together they form heterodimeric adrenomedullin (AM) receptors. We investigated the contributions made by His residues situated in the RAMP extracellular domain to AM receptor trafficking and receptor signaling by co-expressing hCRLR and V5-tagged-hRAMP2 or -3 mutants in which a His residue was substituted with Ala in HEK-293 cells. Flow cytometric analysis revealed that hRAMP2-H71A mediated normal hCRLR surface delivery, but the resultant heterodimers showed significantly diminished [¹²⁵I]AM binding and AM-evoked cAMP production. Expression of hRAMP2-H124A and -H127A impaired surface delivery of hCRLR, which impaired or abolishing AM binding and receptor signaling. Although hRAMP3-H97A mediated full surface delivery of hCRLR, the resultant heterodimers showed impaired AM binding and signaling. Other His residues appeared uninvolved in hCRLR-related functions. Thus, the His residues of hRAMP2 and -3 differentially govern AM receptor function.